Fig. 4: Identification and validation of the SV signatures.
From: Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells
a Kaplan-Meier plot of melanoma patients with high-risk versus low-risk in training cohort. The P values were computed by log-rank test. The proportion of melanoma patients who responded to ICI treatment in the high-risk and low-risk in Liu2019 (b) and Gide2019 cohort (c). The P values were computed by Fisher’s exact test. A significant differential risk score of melanoma patients between response and non-response in Liu2019 (d) and Gide2019 (e) cohort. The P values were computed from one-sided Wilcoxon rank-sum test. f The proportion of melanoma with high TMB in the high-risk and low-risk patients in the Riaz2017 cohort. The P values were computed by Fisher’s exact test. Significant differential neoantigen load (g) and cytolytic score (h) of melanoma patients between high-risk and low-risk in Riaz2017 cohort. The P values were computed by one-sided Wilcoxon rank-sum test. Comparison of C-indexes between the six SV pairs signature and expression (i, j) and mutation (k, l, m) associated signatures from published literature across multiple datasets.
